Clinical Everolimus Experience in Pediatric Renal Transplant Patients

Basit Öğe Kaydı
dc.contributor.authorDincel, N.
dc.contributor.authorBulut, I. K.
dc.contributor.authorSezer, T. O.
dc.contributor.authorMir, S.
dc.contributor.authorHoscoskun, C.
dc.date.accessioned2019-10-27T21:52:29Z
dc.date.available2019-10-27T21:52:29Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description9th Congress of the Turkish-Transplantation-Centers-Coordination-Association (TTCCA) -- SEP 26-29, 2012 -- Bursa, TURKEYen_US
dc.description.abstractObjective. Everolimus is a potent immunosuppressive agent that has antiproliferative activities. This study sought to share our experience among renal transplanted children who required conversion from calcineurin inhibitors (CNIs) to the mammalian target of rapamycin inhibitor everolimus. Patients and Methods. Exclusion criteria were multiple organ transplantations, loss of a previous graft due to immunologic reasons, receipt of an organ donated after cardiac death, donor age <5 years or >65 years, panel reactive antibodies >25%, platelets <75,000/mm(3), absolute neutrophil count of <1,500/mm(3), leucocytes <2,500/mm(3), hemoglobin <6 g/dL, severe liver disease, cold ischemia time >40 hours or anti-HLA panel-reactive antibodies >50%. Results. Eighteen renal transplant patients (10 male, 8 female) underwent conversion to everolimus from CNI: 8 from cyclosporine (CsA) and 10 from tacrolimus. The mean age was 12.6 +/- 0.9 years and the mean body mass index 21.8 +/- 1.7 kg/m(2). The mean 2-hour postdose level of CsA before conversion was 671 +/- 142 ng/mL; the patients on tacrolimus showed a mean trough concentration of 4.5 ng/mL. Six (33,3%) were taking mycophenolate mofetil and 12 (66.6%) enteric-coated mycophenolate sodium. No significant changes were observed in either hepatic functions, serum lipids, or hemograms. There was no mortality or graft loss. The mean level of serum creatinine was 1.3 +/- 0.7 mg/dL before and 1.09 +/- 0.6 mg/dL after conversion. Proteinuria observed in only 1 patient was well controlled with angiotensin-converting enzyme inhibitor therapy. All patients responded to statin therapy. One patient developed unilateral lower extremity edema and 1 a lymphocele. Although there were 3 cases (14%) of biopsy-confirmed acute rejection, there was no mortality or graft loss. Conclusions. Everolimus conversion has become an excellent choice, offering safety and efficacy with good outcomes.en_US
dc.description.sponsorshipTurkish Transplantat Ctr Coordinat Assoc (TTCCA)en_US
dc.identifier.doi10.1016/j.transproceed.2013.02.076en_US
dc.identifier.endpage916en_US
dc.identifier.issn0041-1345
dc.identifier.issue3en_US
dc.identifier.pmid23622585en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage913en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2013.02.076
dc.identifier.urihttps://hdl.handle.net/11454/47648
dc.identifier.volume45en_US
dc.identifier.wosWOS:000318457000017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical Everolimus Experience in Pediatric Renal Transplant Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu